Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has issued an update.
Race Oncology Ltd has announced that it has received Human Research Ethics Committee (HREC) approvals for its Phase 1 clinical trial of RC220 in combination with doxorubicin at two hospitals in Hong Kong. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of RC220, potentially offering cardioprotection and enhanced efficacy for cancer patients. The approvals are expected to expedite patient recruitment and provide crucial clinical evidence in the East Asian market, enhancing Race Oncology’s industry positioning.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, bisantrene, is a small molecule anticancer agent known for its therapeutic benefits and reduced cardiotoxicity compared to certain anthracyclines like doxorubicin.
Average Trading Volume: 120,044
Technical Sentiment Signal: Sell
Current Market Cap: A$199.8M
Learn more about RAC stock on TipRanks’ Stock Analysis page.